Exercise may stop joint pain in breast cancer patients on hormone pills
NCT ID NCT07295457
First seen Jun 27, 2026 · Last updated Jul 31, 2026 · Updated 1 time
Summary
This study tests if starting a personalized exercise program early can prevent or reduce joint and muscle pain caused by aromatase inhibitors, a common hormone therapy for breast cancer. About 182 postmenopausal women with hormone-sensitive breast cancer will either receive the exercise program or usual care. The goal is to see if exercise helps women stay active, feel better, and stick with their cancer treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 182 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
May 2026
- Expected to finish
-
Jul 2029
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 75 years
- Sex
-
Female participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: Quantitative study: * Women aged 18 to 75 * Person with non-metastatic breast cancer * positive for at least one hormone receptor * Person treated with an Aromatase Inhibitor * Person with the following treatment regimen: Surgery - radiotherapy - aromatase inhibitor hormone therapy or surgery - chemotherapy (neoadjuvant or adjuvant) +/- targeted therapy - +/- radiotherapy - aromatase inhibitor hormone therapy. * Person affiliated to a social security scheme * Person having signed a free and informed consent Qualitative study: For patients : * Patient having given consent to participate in the APIS study * Patient agreeing to participate in the qualitative study (box checked on the APIS informed consent form) * Patient agreeing to the recording of the semi-directive interview For healthcare professionals : * Person practicing within the Saint-Étienne University Hospital and the Croix-Rousse University Hospital as a surgeon, oncologist, radiotherapist, sports medicine physician, APA instructor, physiotherapist, head nurse, care coordinator nurse, or advanced practice nurse * Persons working with patients treated with aromatase inhibitors for non-metastatic breast cancer * Person who has received individual information * Person who has given consent to participate in the study * Person agreeing to the recording of the semi-directive interview * Person of legal age Ancillary study : * Eligible patient who has given consent to participate in the APIS study * Patient agreeing to participate in the ancillary study (box checked on the APIS informed consent form) Exclusion Criteria: For all patients: * Person deprived of liberty by judicial or administrative decision * Person under psychiatric care (unstable pathology) * Person of full age under legal protection (guardianship, curatorship) * Person unable to receive sufficient information due to impaired higher functions, or insufficient command of the French language * Person participating in another interventional research study with an exclusion period still in progress at the time of pre-inclusion * Person with absolute contraindications to physical exercise: * Unstable angina * Decompensated heart failure * Complex ventricular rhythm disorders * Uncontrolled severe arterial hypertension * Pulmonary arterial hypertension (\> 60 mm Hg) * Presence of large or pedunculated intracavitary thrombus * Acute pericardial effusion * Severe obstructive cardiomyopathy * Tight and/or symptomatic aortic stenosis * Recent thrombophlebitis with or without pulmonary embolism * Diabetes with plantar perforator disease for physical activity activities involving the lower limbs * Persons with musculoskeletal pathologies making cycling impossible
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Breast cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
2 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Service de Chirurgie Gynécologie-Obstétrique,CHU Hôpital Nord
NOT_YET_RECRUITINGSaint-Priest-en-Jarez, 42270, France
-
Service de Gynécologie-Obstétrique, Groupement Hospitalier Nord, Hospices Civils de Lyon
RECRUITINGLyon, 69317, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a common steroid shield breast cancer patients from a dangerous drug side effect?
- Tiny magnetic seeds could guide surgeons to the right lymph node
- New PET tracer aims to light up hidden cancer targets
- Gut bacteria supplement tested against chemo hair loss
- Can a mindfulness program boost Self-Compassion in breast cancer survivors?
- Can a Decades-Old Anti-Inflammatory drug quiet the joint pain that drives women off breast cancer therapy?